Design Therapeutics
DSGN
100 hedge funds and large institutions have $172M invested in Design Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more capital invested
Capital invested by funds: $108M → $172M (+$64.8M)
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
5% more funds holding
Funds holding: 95 → 100 (+5)
0.24% less ownership
Funds ownership: 56.81% → 56.57% (-0.24%)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
90% less call options, than puts
Call options by funds: $18K | Put options by funds: $175K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.52M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3.28M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.87M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.83M |
| 2 |
Millennium Management
New York
|
-$1.9M |
| 3 |
Goldman Sachs
New York
|
-$1.54M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.41M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$922K |
DSGN Hedge Fund Activity: Q3 2024 in Review
100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2024, worth a combined $172M — up 60% from $108M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DSGN positions and 9 closed out — a net gain of 5 holders — while 30 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.52M. The largest seller was Logos Global Management, cutting an estimated $3.83M.
- 100 institutional investors held Design Therapeutics (DSGN) as of Q3 2024, up from 95 in Q2 2024.
- Funds reported $172M of Design Therapeutics stock for Q3 2024, up 60% quarter-over-quarter.
- 14 funds opened new Design Therapeutics positions in Q3 2024 and 9 closed out, a net change of +5 holders.
- The largest Design Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $3.52M added.
- The largest Design Therapeutics seller in Q3 2024 was Logos Global Management, an estimated $3.83M sold.
Based on aggregated 13F filings for Q3 2024.